Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
ADC Therapeutics
Pharma
Gilead's Yescarta 2L DLBCL bid among winners at EMA
The EMA also recommended an initial approval for a rival to the CAR-T—CD19-targeted antibody-drug conjugate Zynlonta by Sobi and ADC Therapeutics.
Angus Liu
Sep 16, 2022 11:25am
ADC Therapeutics taps Sobi to market Zynlonta outside of US
Jul 8, 2022 10:55am
David Gilman joins Ameet Mallik on ADC Therapeutics' exec board
Jun 14, 2022 3:57pm
ADC Therapeutics lures former Novartis exec as new CEO
May 9, 2022 10:36am
The top 10 antibody-drug conjugate contenders in 2021
Sep 13, 2021 3:00am
Even during pandemic, FDA approvals remain on a rapid pace
Jul 6, 2021 11:27am
